Biologics Tied to Lower Eye Risk in Psoriasis - Quiz - MDSpire

Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.

  • By

  • Andrea Surnit

  • April 20, 2026

  • 2 min

Share

Original Source(s)

Biologics Tied to Lower Eye Risk in Psoriasis

  • by Andrea Surnit

  • April 20, 2026

Related Content

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.